Author

Karina Close

Observed names: Close, K, K. Close, Karina EM Close

Institutions: Queen Mary University of London, Barts Cancer Institute

Observed institutions: Queen Mary University of London, Barts Cancer Institute

ORCID: 0009-0003-4237-4617

Observed ORCID: 0009-0003-4237-4617

OpenAlex ID: A5029905382

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

2021 · James Heward, Lola Koniali, et al. · Blood · 51

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

2020 · Ana Rio-Machin, Pedro Casado-Izquierdo, et al. · Blood · 4

Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma

2024 · Danmei Xu, Findlay Bewicke-Copley, et al. · Blood Cancer Journal · 2

KDM4C in germinal center lymphoma: a new piece of the epigenetic puzzle

2022 · Karina Close, Jude Fitzgibbon · Haematologica · 2

S844 Kdm5 Inhibition Offers a Novel Therapeutic Strategy for the Treatment of Kmt2d Mutant Lymphomas

2019 · J. Heward, L. Koniali, et al. · HemaSphere · 2

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma

2024 · Emil Arjun Kumar, Koorosh Korfi, et al. · British Journal of Haematology · 1

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

2022 · Ana Rio-Machin, Findlay Bewicke-Copley, et al. · Blood

The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas

2021 · Karina Close, Hannah Armes, et al. · Blood

Works count: 9

Citation count: 62

H-index: 2

I10-index: 1